Here is a question we hear at least once a day across our seven locations: "What's the difference between Xeomin and Botox — and which one should I actually get?" Most people asking have already done some research. They've read a handful of articles that all say roughly the same thing: "Both are neurotoxins. Both relax muscles. Botox is more established. Xeomin is 'purer.' Talk to your provider." And then they close the tab just as confused as when they opened it.
Here's the angle those articles are missing: the decision between Xeomin and Botox is less about which product is objectively superior and more about your specific skin biology, treatment history, aesthetic goals, and how your body has responded to neuromodulators in the past. The "pure toxin" talking point is real but often oversimplified. The "Botox is stronger" narrative is frequently misapplied. And the question of longevity — which one lasts longer — depends on factors that most comparison guides never address.
This article is our attempt to actually close the gap. We'll walk through the science without oversimplifying it, break down the real clinical differences, address the most common misconceptions our clients arrive with, and give you a decision framework that reflects what we see in our treatment rooms every day — not just what the manufacturer brochures say.
Understanding Neuromodulators: What Xeomin and Botox Actually Do
Before comparing two products, it's worth establishing a shared foundation — because a surprising number of clients arrive at consultations with fundamental misconceptions about how neuromodulators work, and those misconceptions can distort every decision that follows.
Both Xeomin and Botox are formulations of botulinum toxin type A, a purified protein derived from the bacterium Clostridium botulinum. When injected in small, controlled amounts into targeted facial muscles, botulinum toxin type A temporarily inhibits the release of acetylcholine — the neurotransmitter responsible for triggering muscle contractions. The result is a localized, temporary relaxation of the treated muscle. Wrinkles that are caused or worsened by repetitive muscle movement — crow's feet, forehead lines, frown lines (the "11s") — become visibly smoother as the muscle beneath them quiets down.
This is not a filler. It does not add volume. It does not plump skin from below. It works by reducing the dynamic muscular activity that deepens lines over time. That distinction matters enormously when clients come in asking for a "refresh" without understanding that deeply etched static lines — lines visible even at rest — may respond only partially to neuromodulators alone and may benefit from a combined approach with dermal fillers.
The FDA Approval Landscape in 2026
Both products carry FDA approval for cosmetic use. Botox Cosmetic (onabotulinumtoxinA, manufactured by Allergan/AbbVie) has been FDA-approved for cosmetic indications since 2002 and has the longest track record of any neuromodulator currently on the US market. Xeomin (incobotulinumtoxinA, manufactured by Merz Aesthetics) received FDA approval for cosmetic use in 2011, specifically for the treatment of glabellar lines — the vertical frown lines between the brows.
Both products are also approved for several medical (non-cosmetic) applications including cervical dystonia, blepharospasm, chronic migraine, and hyperhidrosis (excessive sweating), which speaks to the robust safety profile that underpins their cosmetic use. The fact that these molecules are trusted for complex neurological applications gives our clinical team confidence in their safety when used for aesthetic purposes by trained, licensed providers.
Units Are Not Interchangeable
One of the most important technical points that gets lost in consumer-facing content: Botox units and Xeomin units are not identical in potency to Dysport units, though Botox and Xeomin units are generally considered roughly equivalent to each other by most practitioners. This means if you've been getting a specific dose of Botox and you switch to Xeomin, your provider should not simply mirror the same unit count without clinical judgment — though for most patients transitioning between these two specifically, the conversion is relatively straightforward compared to switching to or from Dysport. Always disclose your treatment history in full at every consultation.
Botox: The Gold Standard, and What That Actually Means
Botox is the neuromodulator most people picture when they think about injectable wrinkle treatment. Its cultural ubiquity is real — "getting Botox" has become a generic verb in the way "Googling" stands in for internet searches. But that familiarity cuts both ways: it makes Botox accessible and understood, and it also means the product carries decades of assumptions, myths, and misinformation that can cloud a patient's decision-making.
The Formulation: What's Actually in the Vial
Botox Cosmetic contains onabotulinumtoxinA along with complexing proteins — hemagglutinin and non-hemagglutinin proteins that surround and stabilize the active toxin molecule. These accessory proteins are not active ingredients; they don't cross into the bloodstream or cause systemic effects at the doses used cosmetically. Their primary role is structural — they protect the toxin during manufacturing, storage, and (theoretically) after injection while the molecule is being absorbed by the target nerve terminals.
The presence of these accessory proteins is at the center of the "purity" debate, which we'll address in detail in the Xeomin section. For now, it's worth noting that Allergan has invested heavily in research demonstrating that these proteins do not impair the safety or efficacy of the product, and the clinical record over two-plus decades broadly supports this position.
Onset, Duration, and Predictability
Botox typically begins showing visible results within 3 to 7 days post-injection, with full effect usually apparent by day 14. Duration is commonly cited as 3 to 4 months for most patients, though individual variation is significant. Factors that influence how long Botox lasts include the treatment area, the dose administered, the patient's metabolism, muscle mass and activity level, and whether the patient exercises intensively (high-metabolism, high-activity individuals often metabolize neuromodulators faster).
One genuine advantage of Botox's long market history is the depth of provider familiarity. Because Botox has been the dominant neuromodulator for more than two decades, most injectors — whether nurse practitioners, registered nurses, physician assistants, or physicians — have injected it thousands of times. That accumulated technique knowledge is a real asset. Subtle differences in injection depth, spread pattern, and dose optimization are things that practitioners learn through repetition, and with Botox, the repetition base is enormous.
Who Is Botox Ideal For?
In our clinical experience, Botox tends to be an excellent choice for:
- First-time neuromodulator patients who want the most extensively documented product with a proven safety record
- Patients who have responded well to Botox historically and have no reason to switch
- Clients treating a wide range of areas, since Botox has FDA approval and extensive off-label use data across more treatment zones than any other neuromodulator
- Patients who prefer a product with the widest availability — Botox is stocked at virtually every qualified aesthetic practice in the country
- Individuals managing medical conditions (migraine, hyperhidrosis) concurrently with cosmetic goals, since one product can address both
Pricing Considerations
Botox is typically priced per unit, with pricing varying by geography, provider credentials, and practice type. In a major metro market like New York City, per-unit pricing tends to run higher than national averages. At Skin Spa New York, we price transparently and discuss unit estimates during consultation — because an honest conversation about expected dose is the only way to give clients a realistic cost picture. Be cautious of significantly below-market pricing; it can indicate diluted product, under-dosing, or unlicensed administration.
Xeomin: The "Naked" Neurotoxin and Why That Matters More Than You Think
Xeomin is often described in consumer content as "just like Botox but without the extra proteins," which is technically accurate but misses the clinical significance of that difference — and also overstates it in some contexts. Let's unpack what the "naked neurotoxin" formulation actually means for real patients.
The Formulation: Pure Toxin, No Accessory Proteins
Xeomin contains incobotulinumtoxinA — the same active botulinum toxin type A molecule found in Botox, but without the hemagglutinin and non-hemagglutinin complexing proteins. Merz's manufacturing process uses an additional purification step (they call it their "XTRACT Technology") to remove these accessory proteins before the final product is formulated.
The result is a highly purified toxin that contains only the active 150-kilodalton botulinum toxin molecule. No extra proteins. No stabilizing agents beyond a small amount of human albumin and sucrose used in the final formulation.
Why does this matter? The theoretical clinical relevance is around antibody formation. When any foreign protein is injected into the body repeatedly, the immune system can develop neutralizing antibodies against it. In the context of neuromodulators, antibody formation against the complexing proteins in products like Botox is largely considered clinically irrelevant — those antibodies don't neutralize the active toxin. However, some researchers and clinicians have raised the hypothesis that reducing overall protein load (by eliminating accessory proteins) could theoretically reduce the risk of developing neutralizing antibodies against the active toxin molecule itself over time, particularly in patients who receive high doses or very frequent treatments.
This is not a settled debate. The evidence does not definitively establish that Xeomin's protein-free formulation meaningfully reduces clinically significant antibody resistance in cosmetic patients receiving standard doses. But for patients who have experienced what appears to be reduced efficacy or treatment resistance after years of consistent Botox use, switching to Xeomin is a reasonable clinical consideration — and one we discuss with clients when that pattern emerges.
Storage Advantage: Room Temperature Stability
One practical, underappreciated advantage of Xeomin's formulation is its room temperature stability. Unlike Botox, which requires refrigeration, Xeomin can be stored at room temperature (up to 77°F / 25°C) for up to 36 months. This is a logistics advantage for practices rather than patients, but it does have indirect relevance: it means Xeomin is less susceptible to cold chain failures during shipping and storage, which can theoretically affect product integrity at practices with inconsistent refrigeration protocols. At established medical spas with proper protocols (like ours), this distinction is largely academic — but it's worth knowing.
Onset and Duration: Slightly Different Kinetics
Many practitioners observe that Xeomin may have a slightly slower onset than Botox — often described as 4 to 7 days to initial visible effect versus Botox's 3 to 5 days — though individual variation makes this a soft distinction rather than a hard rule. Some patients report that Xeomin's effect feels more gradual and natural in its onset, which is actually a preference point for certain clients who don't want a rapid, dramatic change visible to coworkers or family.
Duration is generally similar to Botox — roughly 3 to 4 months for most cosmetic patients. Some practitioners and patients report that Xeomin may last slightly shorter at the beginning of treatment but equalizes over time, particularly with consistent maintenance. This is an area where individual biology plays a larger role than formulation differences.
Who Is Xeomin Ideal For?
- Experienced neuromodulator patients who have noticed diminishing returns from Botox over time and want to explore whether a different formulation produces a better response
- Patients who are interested in a highly purified product with minimal excipient proteins
- Clients who prefer the perceived "cleaner" formulation from a personal philosophy standpoint — many of our clients are health-conscious professionals who care about exactly what goes into their bodies
- Patients treating glabellar lines specifically, since this is Xeomin's primary FDA-approved cosmetic indication
- Anyone whose provider recommends it based on their specific treatment history and skin assessment
Head-to-Head Comparison: Xeomin vs. Botox Across Key Clinical Dimensions
The following table synthesizes the most clinically relevant comparison points between Xeomin and Botox for cosmetic use. This is designed to give you a clear, scannable reference — but remember that individual variation means no table can substitute for a personalized consultation.
| Feature | Botox (onabotulinumtoxinA) | Xeomin (incobotulinumtoxinA) |
|---|---|---|
| Manufacturer | Allergan / AbbVie | Merz Aesthetics |
| Active Ingredient | Botulinum toxin type A + complexing proteins | Botulinum toxin type A only (no complexing proteins) |
| FDA Cosmetic Approval | 2002 (glabellar lines, crow's feet, forehead lines) | 2011 (glabellar lines) |
| Onset of Effect | 3–7 days; full effect by day 14 | 4–7 days; full effect by day 14 |
| Duration | 3–4 months (typical range) | 3–4 months (typical range) |
| Storage Requirements | Refrigeration required (2–8°C) | Room temperature stable (up to 25°C, 36 months) |
| Complexing Proteins | Present (hemagglutinin + non-hemagglutinin) | Absent (pure toxin formulation) |
| Unit Equivalency | 1 unit Botox ≈ 1 unit Xeomin | 1 unit Xeomin ≈ 1 unit Botox |
| Provider Familiarity | Extremely high — 20+ years of use | High — 15+ years of US use |
| Resistance/Antibody Concern | Theoretical concern with long-term high-dose use | Theoretically lower risk due to reduced protein load |
| Typical Pricing Model | Per unit or per area; widely variable by market | Per unit or per area; typically comparable to Botox |
| Best For | First-timers, broad treatment areas, established responders | Experienced patients, those exploring resistance, health-conscious clients |
The Resistance Question: When Long-Term Botox Users Should Consider Switching
This is arguably the most clinically important and least discussed topic in the Xeomin vs. Botox conversation. Treatment resistance — or more accurately, apparent treatment resistance — is a real phenomenon, and understanding it can fundamentally change how a long-term injectable client thinks about their options.
What "Resistance" Actually Looks Like
True immunological resistance to botulinum toxin type A (where the body produces neutralizing antibodies against the active toxin molecule) is considered rare in cosmetic patients receiving standard doses on standard schedules. It is more commonly documented in patients receiving very high doses for therapeutic indications like cervical dystonia.
However, what many cosmetic patients and even some providers describe as "resistance" is often one of the following:
- Under-dosing: As patients become more experienced with neuromodulators, their expectations for visible relaxation often increase. What was sufficient 3 years ago may feel insufficient today — not because the product stopped working, but because the patient's aesthetic standard has evolved. The solution here is a dose adjustment, not a product switch.
- Metabolic acceleration: Some patients genuinely metabolize neuromodulators faster over time, particularly as they become more physically active or experience hormonal changes. This is a pharmacokinetic change, not an immunological one.
- Muscle adaptation: Facial muscles that have been partially relaxed for years develop different movement patterns. Some patients find that previously treated muscles require more precise targeting as anatomy subtly shifts.
- True antibody formation: Rare, but possible. In these cases, switching to a different neuromodulator formulation — including Xeomin's protein-free version — is a reasonable clinical step, as any antibodies formed against the accessory proteins in Botox would be irrelevant to Xeomin's pure toxin formulation.
At our Manhattan locations, we see this pattern regularly: a client who has been a loyal Botox user for 7 or 8 years comes in reporting that their results "aren't lasting as long" or "don't look as crisp." Our clinical team's first step is always a thorough reassessment — reviewing dose history, lifestyle factors, and treatment intervals — before attributing the change to product tolerance and recommending a switch. Sometimes the answer is simply increasing the dose or adjusting injection technique. Other times, a trial of Xeomin genuinely produces a different and more satisfying outcome.
The Rotation Strategy: What Some Experienced Injectors Recommend
Some experienced injectors advocate for periodically rotating between neuromodulator products — alternating between Botox, Xeomin, and Dysport — as a strategy to minimize the theoretical risk of antibody accumulation over time. This approach lacks robust clinical trial evidence in cosmetic patients, but the rationale is not unreasonable: exposing the immune system to different protein profiles at different times could theoretically reduce the likelihood of building a strong antibody response to any one formulation's protein signature.
This is not a universally adopted approach, and it requires a provider with experience in multiple neuromodulators and the ability to manage the different dose conversion and technique nuances each product demands. It's worth asking your provider about if you're a high-frequency, long-term injectable client who wants to think proactively about long-term outcomes.
The Patient Experience: What Injections Feel Like, Recovery, and Managing Expectations
For clients who have never had a neuromodulator treatment — or who are considering switching products — understanding the practical experience of the appointment itself is important. The clinical differences between Xeomin and Botox are largely invisible to the patient during the treatment itself; both are administered via very fine-gauge needles into targeted facial muscles, both take approximately 15 to 30 minutes depending on the number of areas treated, and both involve the same general pre- and post-care protocols.
Before Your Appointment
Standard pre-treatment guidance for both Botox and Xeomin includes:
- Avoiding blood thinners (including aspirin, ibuprofen, fish oil, vitamin E, and alcohol) for approximately 1 week before treatment to minimize bruising risk
- Disclosing all medications, supplements, and medical history — certain medications (particularly aminoglycoside antibiotics) can potentiate neurotoxin effects
- Arriving with a clean face, free of makeup
- Not scheduling treatment immediately before a major event — allow at least 2 weeks for full results to appear and any minor bruising or swelling to resolve
- Disclosing pregnancy or breastfeeding status — neuromodulators are not recommended during pregnancy or lactation
During Treatment
Both products are injected using a very fine needle. Most patients describe the sensation as a brief, mild pinch at each injection point. The number of injection points varies by treatment area and provider technique — glabellar lines might require 5 injection points, while a full-face treatment covering forehead, glabella, crow's feet, and other areas might involve 15 to 25 individual injections. Topical numbing cream can be applied beforehand for patients with sensitivity concerns, though many experienced patients find it unnecessary.
The physical experience of a Botox injection versus a Xeomin injection is essentially identical. The needle, the sensation, the technique — there is nothing in the injection experience itself that distinguishes one product from the other.
After Treatment
Post-treatment instructions for both neuromodulators are similar:
- Remain upright for 4 hours post-injection (avoid lying down)
- Avoid rubbing or massaging the treated area for 24 hours
- Skip intense exercise for 24 hours
- Avoid significant heat exposure (saunas, hot yoga, steam rooms) for 24 to 48 hours
- Expect possible minor redness, swelling, or pinpoint bruising at injection sites — these typically resolve within 24 to 48 hours
- Do not schedule laser treatments, facials, or other facial procedures in the same area for at least 2 weeks
A common question we receive after treatment: "I can still move my forehead — did it work?" Yes, almost certainly. Results take time to appear. The full effect typically isn't visible until day 10 to 14. If at day 14 you feel the result is insufficient, contact your provider to discuss a complimentary touch-up rather than assuming the product failed.
Xeomin and Botox for Specific Treatment Areas: A Clinical Breakdown
The choice between Xeomin and Botox can also shift depending on the specific area being treated. While both are versatile neuromodulators, some clinical nuances are worth understanding by treatment zone.
Glabellar Lines (The "11s")
This is the primary FDA-approved cosmetic indication for both products. Both Botox and Xeomin perform consistently in this area, and it's where most clinical comparison data exists. For first-time patients, either product is appropriate. For patients with significant glabellar depth (deep-set static lines visible at rest), a combined approach using neuromodulator plus a small amount of hyaluronic acid filler may produce more comprehensive improvement — a combination our team at Flatiron and Union Square frequently customizes for clients with well-established glabellar creasing.
Forehead Lines
Forehead treatment requires precise dosing and careful technique to avoid over-relaxation of the frontalis muscle, which can lead to brow heaviness or ptosis. Both products can be used effectively, but the treating provider's technique and experience matter enormously in this area. Underdosing (leaving visible movement) is generally preferable to overdosing (creating a heavy, immobile brow), especially for patients new to forehead treatment.
Crow's Feet
Both products work well for periorbital wrinkles. Some practitioners observe that Botox's slightly broader diffusion pattern (potentially related to the presence of complexing proteins influencing spread) can be advantageous in this area, where a slightly wider area of relaxation can produce a smooth, natural result. However, this is a practitioner-level nuance rather than a patient-facing decision point — an experienced injector will adjust technique regardless of which product is used.
Brow Lift ("Chemical Brow Lift")
A small amount of neuromodulator injected under the brow can produce a subtle but meaningful lifting effect by relaxing the depressor muscles that pull the brow downward. Both Xeomin and Botox are used off-label for this purpose. The effect is modest — typically 1 to 3 millimeters of lift — but can make a meaningful cosmetic difference for patients with mild brow ptosis or those seeking a more open, refreshed appearance without surgical intervention.
Lip Lines, Neck Bands, and Advanced Areas
As neuromodulator treatment moves into more advanced anatomical areas — perioral lines ("lip flip"), platysmal bands in the neck, masseters for jawline slimming, hyperhidrosis treatment — the importance of provider expertise grows substantially. Both products are used in these areas, largely based on provider preference and experience. We recommend that patients seeking treatment in any off-label or advanced area specifically ask about their provider's experience in that zone and review before/after photography where available.
The "GlowTox" and Combination Treatment Context
One of the most popular treatment frameworks we've developed across our Skin Spa locations combines neuromodulator treatment with complementary procedures for a comprehensive result that neither modality can achieve alone. Understanding where neuromodulators fit within a broader aesthetic plan helps clients make smarter decisions — including whether Botox or Xeomin is the right neuromodulator for their specific combination protocol.
Our "GlowTox" approach pairs neuromodulator treatment with skin-surface treatments — typically a HydraFacial, PCA peel, or Laser Genesis — to address both muscle-driven dynamic lines (neuromodulator's domain) and skin texture, tone, and radiance (the surface treatment's domain). This dual-layer approach consistently produces more comprehensive results than either treatment in isolation, because lines and wrinkles have two contributing factors: muscle movement and skin quality. Treating only one leaves the other unaddressed.
From a product selection standpoint within this framework: both Botox and Xeomin integrate equally well with surface treatments. We typically schedule the neuromodulator injection first, then perform any surface treatments at a separate appointment (or at the same appointment but to a different area) to avoid any potential interaction at the injection sites. Your provider will map out the optimal sequencing based on your full treatment plan.
Similarly, when clients are receiving dermal fillers (Juvéderm or Restylane collections) alongside neuromodulators — a very common combination for comprehensive facial rejuvenation — the choice of Botox versus Xeomin doesn't change the filler protocol. The two product categories act through completely different mechanisms and on different anatomical targets, and they complement each other without interference.
Our Provider-Side Decision Framework: How We Actually Choose
Here is something most comparison articles don't give you: a transparent look at how the decision actually gets made on the clinical side. When a patient sits down for an injectable consultation at any of our seven locations, here is the genuine decision process our providers work through when considering Botox versus Xeomin.
Step 1: Treatment History Assessment
We ask about every neuromodulator the patient has received, at what dose, at what interval, and what their satisfaction was with each treatment. If a patient has been consistently happy with Botox for 5 years, there is generally no compelling reason to switch. If they report declining satisfaction — less duration, less apparent relaxation — we probe deeper to distinguish true tolerance from under-dosing, technique issues, or changed expectations.
Step 2: Treatment Goals and Lifestyle Context
A patient who travels frequently for work and values the logistical simplicity of a single well-established product available everywhere may prefer to stay on Botox. A patient who is deeply interested in the "purity" narrative and has done their own research on complexing proteins may feel more confident with Xeomin. Both are valid considerations. Our job is not to override patient preference but to inform it with clinical context.
Step 3: Area-Specific Considerations
As described above, certain treatment areas may favor one product's diffusion characteristics. Our providers make this determination based on the specific areas being treated, the patient's anatomy, and the desired endpoint.
Step 4: Budget and Access
Pricing for Botox and Xeomin is generally comparable in the NYC market, though promotional pricing and loyalty programs (Botox's Allē program, Merz's Xperience rewards) can create real differences in out-of-pocket cost for returning patients. We always make sure clients are aware of available savings programs. Long-term, the loyalty points earned through consistent treatment with one product can represent meaningful savings — worth factoring into a multi-year treatment plan.
The Framework in Summary
| Patient Scenario | Recommended Starting Point | Reasoning |
|---|---|---|
| First-time neuromodulator patient | Botox | Deepest clinical track record, highest provider familiarity, most extensively documented safety profile |
| Experienced patient with consistent Botox satisfaction | Continue Botox | No compelling clinical reason to switch a reliably effective protocol |
| Long-term patient reporting declining results | Reassessment first; consider Xeomin trial | Rule out dose/technique factors; if those are optimized, Xeomin's different formulation may produce better response |
| Health-conscious patient preferring minimal excipients | Xeomin | Protein-free formulation aligns with patient's values; clinically equivalent efficacy |
| Patient primarily treating glabellar lines | Either product appropriate | Both have FDA approval for this indication; provider preference and patient history guide selection |
| Patient treating multiple advanced areas | Botox (primary); consult provider for area-specific guidance | Broader FDA approval scope and deeper off-label use data across diverse anatomical zones |
| Patient on loyalty/rewards program | Continue current product for rewards continuity | Long-term savings from accumulated rewards can be significant; switching products resets rewards progress |
What About Dysport? Where It Fits in the Conversation
Any honest comparison of Xeomin and Botox in 2026 should briefly acknowledge Dysport (abobotulinumtoxinA, manufactured by Galderma), the third major neuromodulator in the US market — not because this article is about Dysport, but because many clients ask about it and it's important to have a complete frame of reference.
Dysport contains botulinum toxin type A plus accessory proteins (like Botox, not Xeomin), but its unit potency is different — roughly 2.5 to 3 Dysport units are equivalent to 1 Botox unit, which means the raw unit numbers on your invoice are not comparable across these products without a conversion. Dysport is often noted for spreading slightly more broadly from the injection point, which can be an advantage (for large treatment areas like the forehead) or a disadvantage (near sensitive structures like the brow where precise containment is important). It is a legitimate, FDA-approved option that many patients and providers prefer, but it belongs in a separate, dedicated comparison.
For the Xeomin vs. Botox decision specifically, the key takeaway is: Dysport is neither superior nor inferior to either — it's a different formulation with different dosing math and different diffusion characteristics that may suit certain patients and treatment goals. Your provider can help you understand whether it belongs in your personal rotation.
Frequently Asked Questions About Xeomin vs. Botox
Is Xeomin stronger than Botox?
No — Xeomin is not stronger than Botox. Both products contain botulinum toxin type A as the active ingredient, and at equivalent doses (approximately 1:1 unit ratio), they produce comparable levels of muscle relaxation. "Stronger" is not the right framework; more relevant questions are about duration, onset, and individual response.
Can I switch from Botox to Xeomin mid-treatment cycle?
You shouldn't need to switch mid-cycle — neuromodulator results last several months, and products should not be mixed or layered during an active treatment period. When your current treatment has fully worn off, your provider can assess whether switching products makes sense for your next session.
Will Xeomin work if Botox has stopped working for me?
It may. If you've developed true immunological resistance to Botox (rare), Xeomin's protein-free formulation could produce a better response because it doesn't share the same accessory protein profile. If your "resistance" is actually under-dosing or technique-related, switching products alone won't resolve it. A thorough provider assessment is essential before attributing declining results to product tolerance.
Is Xeomin safer than Botox?
Both products have robust safety profiles supported by extensive clinical use. Xeomin is not categorically safer than Botox — it simply has a different formulation with fewer protein components. Both products share the same active molecule and the same mechanism of action. Safety in practice depends far more on provider qualifications, technique, and appropriate patient selection than on which of these two products is used.
How long does Xeomin last compared to Botox?
Both products typically last approximately 3 to 4 months for most cosmetic patients in standard treatment areas. Individual variation is significant and influenced by factors including dose, metabolism, activity level, treatment area, and muscle mass. Neither product reliably outlasts the other by a meaningful margin in head-to-head clinical observations.
Does Xeomin hurt more than Botox to inject?
No. The injection experience is essentially identical for both products. Both use the same fine-gauge needles, the same technique, and the same injection volumes. Any discomfort is related to the needle itself, the injection site, and individual pain threshold — not to which product is in the syringe.
Can I get Xeomin and Botox at the same appointment?
This is generally not recommended by experienced providers. There is no established clinical protocol for mixing neuromodulator products in the same session, and doing so would complicate any assessment of which product produced what result. If you're switching products, wait for the previous treatment to fully wear off before starting the new one.
Is Xeomin FDA-approved for all the same areas as Botox?
No. Botox Cosmetic has FDA approval for glabellar lines, crow's feet, and forehead lines. Xeomin's FDA cosmetic approval covers glabellar lines only. Both products are used off-label for many additional areas (brow lift, lip flip, neck bands, masseters, etc.) by experienced providers, but Botox has a broader scope of on-label cosmetic indications. Off-label use by qualified providers is standard medical practice and does not indicate experimental or unsafe treatment.
Is Xeomin available at Skin Spa New York?
Yes. We offer Xeomin alongside Botox and Dysport at our Manhattan locations. During your consultation, your provider will discuss which neuromodulator best fits your treatment history, goals, and anatomy. We're product-agnostic in the best sense — our recommendation is always based on what's right for your skin, not on product affiliation.
How much does Xeomin cost compared to Botox?
Per-unit pricing for Xeomin and Botox is generally comparable in the NYC market. The total cost of a treatment depends primarily on how many units are used, which varies by treatment area and individual anatomy. We price per unit and provide transparent unit estimates during consultation so there are no billing surprises. Ask your provider about available rewards programs for both products, which can produce meaningful savings over time.
How do I know which neuromodulator is right for me?
The most reliable answer comes from an in-person consultation with a licensed, experienced provider who reviews your full treatment history, assesses your anatomy, and discusses your goals. General comparison guides (including this one) provide a useful knowledge foundation, but they cannot substitute for individualized clinical assessment. If you're in the New York area, we welcome you to book a consultation at any of our Manhattan locations.
What should I look for in a provider for neuromodulator treatment?
Look for licensed medical professionals (RN, NP, PA, MD, or DO) with specific training in aesthetic injectables — not just a general medical license. Ask about their experience with the specific product you're considering, the number of treatments they perform per month, and whether they have a supervising medical director on-site or available. At Skin Spa New York, all injectable treatments are performed by trained, licensed medical providers under the oversight of our Medical Director, Daphne Duren, DNP.
Our Honest Recommendation: Which One Should You Choose in 2026?
After 20+ years of treating clients across our Manhattan, Boston, and Miami locations, here is our most honest, straightforward take on the Xeomin vs. Botox question — the answer we'd give a close friend asking over coffee, stripped of marketing language.
If you're new to neuromodulators: start with Botox. Not because Xeomin is inferior — it isn't — but because Botox's 24-year clinical record, unmatched provider familiarity, and broad FDA approval scope make it the lower-risk starting point when your provider is learning your individual response. You can always switch later.
If you're an experienced Botox user who is genuinely satisfied: stay with what works. The grass-is-greener appeal of trying Xeomin is understandable, but a reliably effective treatment protocol is worth preserving. Switching for its own sake introduces unnecessary variables.
If you've been a long-term Botox user and are noticing diminishing results: explore Xeomin, but only after a thorough reassessment. The first step is ruling out dose and technique factors with your current provider. If those are genuinely optimized and you're still not satisfied, a Xeomin trial is a clinically reasonable next step — and one we've seen produce meaningful improvement in a subset of our longer-term injectable clients.
If you're health-conscious and the protein-free formulation matters to you philosophically: Xeomin is a confident choice. The clinical efficacy is equivalent. The purity distinction is real, even if its practical significance in standard cosmetic dosing is still being studied. If it aligns with how you think about what you put in your body, that's a legitimate reason to choose it.
What we want every client to take away from this conversation is that the product choice, while worth understanding, is secondary to the quality of the provider and the quality of the consultation. The best Xeomin in the hands of an inexperienced injector will produce worse results than competently administered Botox. The most expensive neuromodulator in the world cannot compensate for inadequate assessment, poor technique, or insufficient follow-up. Choose your provider first. Then choose your product together.
If you're ready to have this conversation in person — whether you're a first-timer or a longtime injectable client looking for a fresh perspective — we invite you to book a consultation at any of our Skin Spa New York locations. Our licensed injectors across Flatiron, Union Square, Midtown East, Upper West Side, Tribeca, Back Bay, North Station, and Miami Beach are ready to build a treatment plan around your specific goals, history, and anatomy. The best neuromodulator is the one that's right for you — and we'll help you figure out exactly what that means.